Girgsdies O E, Rosenkranz G
Behringwerke AG, Marburg, Germany.
Vaccine. 1996 Oct;14(15):1421-8. doi: 10.1016/s0264-410x(96)00081-3.
A total of 522 children between 18 months and 14 years and 191 adults between 18 and 60 years were vaccinated with TBE-vaccine according to an abbreviated schedule (0, 7, 21). The aim of the study was to investigate whether reducing the amount of antigen in the vaccination for children would preserve an adequate immune response and decrease the rate of side-effects. Efficacy was determined on the extent to which children, vaccinated with the low doses (0.4 microgram or 0.75 microgram), reacted by developing antibodies in the same way as adults treated with the approved dose of 1.5 micrograms (equivalence of titres). The titres obtained in the children with the two lower doses were equivalent to those in the adults obtained with the standard dose. Titres decreased in the children with increasing age. Children older than 12 years in the approved dosage group had the same median titres as adults. The frequency of side-effects in the two lower dose groups, especially raised temperature, was markedly reduced. Whereas 30.1% of the children vaccinated with the approved dose had raised temperature higher than 38 degrees C only 18.8% and 18.4%, respectively, of the children vaccinated with the lower doses developed such temperatures. This improved tolerance in terms of raised temperature was also reflected in the other general reactions such as tiredness, joint pain or headache.
共有522名18个月至14岁的儿童和191名18至60岁的成年人按照简略接种程序(0、7、21天)接种了蜱传脑炎疫苗。该研究的目的是调查减少儿童疫苗接种中的抗原量是否能维持足够的免疫反应并降低副作用发生率。通过比较接种低剂量(0.4微克或0.75微克)疫苗的儿童产生抗体的反应程度与接种批准剂量1.5微克疫苗的成年人(抗体滴度等效性),来确定疫苗效力。两个较低剂量组儿童获得的滴度与标准剂量组成年人获得的滴度相当。儿童的滴度随年龄增长而下降。批准剂量组中12岁以上儿童的中位滴度与成年人相同。两个较低剂量组的副作用发生率,尤其是体温升高,明显降低。接种批准剂量疫苗的儿童中,30.1%体温超过38摄氏度,而接种较低剂量疫苗的儿童中,这一比例分别仅为18.8%和18.4%。这种在体温升高方面耐受性的改善也体现在其他一般反应中,如疲劳、关节疼痛或头痛。